Business Wire

AL-ADTRAN

5.12.2023 14:01:36 CET | Business Wire | Press release

Share
Adtran’s Mosaic One simplifies network operations for over 300 new customers

Adtran today celebrated adding over 300 new Mosaic One customers in under 18 months. The rapid adoption of Adtran’s cloud-based software-as-a-service (SaaS) platform highlights its ability to address the demands of modern broadband networks. Mosaic One optimizes network operations by utilizing advanced AI-driven algorithms to anticipate and resolve issues before they impact performance. Its three dedicated portals - Care, Operate and Promote – enable service providers to manage complex deployments, reduce costs and deliver superior services to their subscribers. What’s more, Mosaic One is vendor- and technology-neutral, providing an all-encompassing monitoring solution for FTTH, DOCSIS, DSL and fixed wireless networks across multiple vendors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205627594/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Adtran’s Mosaic One helps service providers maximize the value of their fiber networks. (Photo: Business Wire)

“DFN’s partnership with Adtran and Mosaic One delivers real-time data and insights for our network and customer service teams, allowing us to care for our customers and fiber network proactively and efficiently,” said Todd Way, CEO of DFN. “The Mosaic Marketing Center has also been a considerable time and cost saver for DFN. Our marketing manager can quickly execute and customize community-centered campaigns with the click of a few buttons. Mosaic One positively impacts our operations, our employees and our customers.”

Mosaic One is a vendor- and technology-agnostic solution designed to adapt to the evolving needs of both service providers and end-users. With its predictive insights, real-time monitoring and intuitive user interface, it provides new opportunities and alleviates the workload for support teams, network engineers and marketers. It’s also recently been enhanced with several new features and capabilities. These include Intellifi®, Adtran’s cloud-managed Wi-Fi solution. This provides service providers with unprecedented control over the home Wi-Fi experience, maximizing customer satisfaction, loyalty and spend.

Additionally, the newly introduced Mosaic Marketing Center is a comprehensive marketing platform, offering professionally produced promotional materials, including videos, animated explainers and local stock photography to amplify campaigns. It features an instant customization tool, enabling swift branding and deployment of content, ensuring service providers can quickly tailor and launch their marketing initiatives. Also integrated into the platform is the Fiber Gaming Network, a fully managed turnkey solution for esports management, presenting fresh avenues for revenue growth.

“In less than 18 months, Mosaic One has hit a huge milestone. We often talk about how it empowers service providers to maximize the value of fiber networks. But Mosaic One’s success is also due to the fact that it gives customers what they need — a service with no hidden fees and no additional charges post-deployment. Many of our new customers came to us drained by the intricate licensing and perplexing invoicing their prior vendors used. Instead, what you get with Mosaic One is one invoice, one service, one incredibly easy way to manage your entire network,” commented Robert Conger, GM of software platforms at Adtran. “Achieving 300 deployments in such a short period is impressive, but for Mosaic One, it’s just the beginning. With more service-enhancing and revenue-boosting features in the pipeline, we’ll help shape a new era of opportunity for service providers.”

About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by
ADTRAN Holdings, Inc.
www.adtran.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231205627594/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye